glp 1 sleep apnea Zepbound: Weight Loss Drugs Can Help Reduce Symptoms glp-1 approved for sleep apnea

Scalp preparation: The treatment area is cleaned and topical numbing is applied for comfort

After a median follow-up of 3.2 years (duration of drug exposure 2.4 years) the primary outcome was reduced in the exenatide treated group, but this difference just missed achieving statistical significance (HR 0.91

Folic acid fortification, folate status and plasma homocysteine

The paper, titled Exploring the Relationship Between Newly Defined Continuous Glucose Monitoring (CGM) Metrics and the Standard CGM Metrics in 30,000 People with Type 1 Diabetes, highlights important insights into how emerging CGM metrics relate to established standards in a large cohort